Holpuch Andrew S, Desai Kashappa-Goud H, Schwendeman Steven P, Mallery Susan R
Division of Oral Maxillofacial Surgery, Pathology and Anesthesiology, College of Dentistry, The Ohio State University, Columbus, OH 43210, USA.
J Carcinog. 2011;10:23. doi: 10.4103/1477-3163.85185. Epub 2011 Sep 21.
Due to its characterized progression from recognized premalignant oral epithelial changes (i.e., oral epithelial dysplasia) to invasive cancer, oral squamous cell carcinoma represents an optimal disease for chemopreventive intervention prior to malignant transformation. The primary goal of oral cancer chemoprevention is to reverse, suppress, or inhibit the progression of premalignant lesions to cancer. Over the last several decades, numerous oral cancer chemoprevention clinical trials have assessed the therapeutic efficacy of diverse chemopreventive agents. The standard of care for more advanced oral dysplastic lesions entails surgical excision and close clinical follow-up due to the potential (~33%) for local recurrence at a similar or more advanced histological stage. The purpose of this review was to identify prominent oral cancer chemoprevention clinical trials, assess their overall therapeutic efficacy, and delineate effects of local versus systemic drug administration. In addition, these compiled clinical trial data present concepts for consideration in the design and conduction of future clinical trials.
由于口腔鳞状细胞癌具有从公认的癌前口腔上皮改变（即口腔上皮发育异常）发展为浸润性癌的特征，它是恶性转化前进行化学预防干预的理想疾病。口腔癌化学预防的主要目标是逆转、抑制或阻止癌前病变发展为癌症。在过去几十年中，众多口腔癌化学预防临床试验评估了多种化学预防剂的治疗效果。对于更高级别的口腔发育异常病变，由于在相似或更高级别组织学阶段存在局部复发的可能性（约33%），标准治疗方法是手术切除并密切临床随访。本综述的目的是识别突出的口腔癌化学预防临床试验，评估其总体治疗效果，并阐明局部给药与全身给药的效果。此外，这些汇总的临床试验数据为未来临床试验的设计和实施提供了可供考虑的概念。
